Gastrointestinal and liver disease-focused Metacrine has filed to go public having raised $125m from investors including Eli Lilly.

US-based liver and gastrointestinal disease drug developer Metacrine filed for a $100m initial public offering on the Nasdaq Global Market on Monday that will give pharmaceutical firm Eli Lilly the chance to exit.

The IPO proceeds will fund phase 2a clinical trials for the company’s two lead product candidates, MET409 and MET642, in a liver disease  called non-alcoholic steatohepatitis (NASH).

Metacrine also plans to channel the proceeds into a phase 2a trial for one of the candidates in a…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn